Moy Bracken, Research Unit Manager at Access to Medicine Foundation, shared a post on LinkedIn:
“Emerging markets are no longer simply future growth markets; many are already becoming central to the pharmaceutical industry’s global strategy. This creates a dual opportunity for pharmaceutical companies: to build sustainable growth in increasingly important markets, while also reaching more patients with their medicines.
The Access to Medicine Foundation has just published a trend analysis looking at how 20 of the world’s largest R&D-based pharmaceutical companies are engaging in 10 of the fastest-growing emerging markets.
Using data from the latest Access to Medicine Index, the analysis looks at companies’ registration, supply and R&D pipeline activity to understand which companies are taking a global forward-looking approach and where there is still untapped potential to expand access as these markets continue to grow.
Other articles featuring Moy Bracken on OncoDaily.